Follow-up: A Bayesian Perspective on the FDA Guidelines for Adaptive Clinical Trials

In September 2018, the American Food and Drug Administration (FDA) issued a draft version of the industry guidance on “Adaptive Designs for Clinical Trials of Drugs and Biologics”. In an earlier blog post we provided some comments from a Bayesian perspective that we also submitted as feedback to the FDA. Two months ago, the FDA …